Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,739.50
Bid: 1,739.00
Ask: 1,740.00
Change: -7.00 (-0.40%)
Spread: 1.00 (0.058%)
Open: 1,748.50
High: 1,752.50
Low: 1,737.50
Prev. Close: 1,746.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Ignoring WHO call, major nations stick to vaccine booster plans

Thu, 05th Aug 2021 09:09

* Global body disapproves of boosters until more people
vaccinated

* Some rich nations going ahead anyway to fend off Delta
variant

* Elderly and vulnerable to benefit first from booster shots

* Low-income nations suffer from lack of vaccine supplies
(Adds details throughout)

By Sudip Kar-Gupta and Caroline Copley

PARIS/BERLIN, Aug 5 (Reuters) - Germany, France and Israel
will go ahead with plans to administer COVID-19 vaccine
boosters, disregarding an appeal by the World Health
Organisation to hold off until more people are vaccinated around
the world.

The decision to press ahead with booster shots despite the
WHO's strongest statement yet highlights the huge inequities in
responses to the pandemic as richer nations ramp up programmes
to protect citizens from the more infectious Delta variant.

French President Emmanuel Macron said France was working on
rolling out third doses to the elderly and vulnerable from
September.

Germany intends to give boosters to immunocompromised
patients, the very elderly and nursing home residents from
September, the health ministry said.

Israeli Prime Minister Naftali Bennett urged older citizens
to get a third shot after the government last month kicked off a
campaign to give booster doses.

"Whoever is over the age of 60, and has yet to receive the
third dose of the vaccine, is six times more susceptible to
severe illness and - heaven forbid - death," Bennett said in a
statement.

WHO chief Tedros Adhanom Ghebreyesus called on Wednesday for
a halt to boosters until at least the end of September, saying
it was unacceptable for rich countries to use more of the global
vaccine supply.

INEQUALITIES MOUNT

High-income countries administered around 50 doses for every
100 people in May, and that number has since doubled, according
to WHO. Low-income countries have only been able to administer
1.5 doses for every 100 people, due to lack of supplies.

"I understand the concern of all governments to protect
their people from the Delta variant. But we cannot accept
countries that have already used most of the global supply of
vaccines using even more of it," Tedros said.

Germany rejected those accusations, saying it would also
donate at least 30 million vaccine doses to poorer countries.

"We want to provide the vulnerable groups in Germany with a
precautionary third vaccination and at the same time support the
vaccination of as many people in the world as possible," the
health ministry said.

Following Tedros' comments, the White House said on
Wednesday it was prepared to provide booster shots if needed,
suggesting it would not heed the WHO's call either.

Pfizer has said boosters are most likely needed
because of waning antibody responses, particularly after six
months.

U.S. health regulators have said that more scientific
evidence is needed to be certain boosters are needed, but have
indicated they believe a third shot may be needed for people
with compromised immune systems.

Macron's government is trying to step up France's
vaccination programme as the country faces a fourth wave of the
virus and street demonstrations in protest against the
government's COVID policies.

France and Germany have so far given at least one dose of a
COVID-19 vaccine to 64.5% and 62% of their respective
populations, with 49% of the French and 53% of Germans fully
vaccinated.

(Reporting by Sudip Kar-Gupta and Nicolas Delame in Paris,
Alexander Ratz and Caroline Copley in Berlin; Editing by Nick
Macfie, Josephine Mason, Andrew Cawthorne)

More News
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more
11 Oct 2023 07:47

LONDON BRIEFING: Stocks lower; GSK settles Zantac case in California

(Alliance News) - Stocks in London are set to open lower on Wednesday as investor looked ahead to the release of the US Federal Reserve's September meeting minutes later in the day.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.